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SURVIVAL WITH ANGIOTENSIN-CONVERTING-ENZYME 
INHIBITION VS. DIRECI’ VASODILATION FOR THE SAME 
HEMODYNAMIC GOALS IN ADVANCED HEART FAILURE: 
106 RANDOMIZED PATIENTS. QQ?P Fonarow, Cathc5ne 
Chelimsky-Fallick, Lynne W. Stevenson, Michael Luu, Michele 
Hamilton, Jaime Moriguchi, Julie Walden, Elaine Aibanese, Jan 
Till&h. UCLA Medical Center, Los Angeles, CA. 
Both angiotensin-converting-enzyme inhibition (ACEI) and direct 
vasodilation reduce heart failure mortality, but have not been 
compared in a randomized trial. We randomized 106 pts evaluated 
for transplant to captopril (ACEI! QF !tydrala.zine/isordil (H/I) 
titrated to match the hemodynamks a,~!neved on nitroprusside + 
diuretics to approach SVB 1200 d-set-cm’s and PCW 15 mm, with 
oral drug crossover for poor hemodynamics or side effects (46% 
from ACEI! 28% from* 
H/I). Pts discharged on 
ACEI had same 
EF=.20. initial RA=13 
Probrblllly 01 Survival 
mm, PdW=27 mm, CO 60% 
3.1-3.21, and SVR 1830- 
1920. On discharge 40% I I- f 
regimen, final RAs were 20.; - cmoel~l 
7 mm, SVRs 1150, Na - **1,oltn1 
134 vs 133, final PCWs ‘0- 3 9 12 
16 vs 18 mm (p= .OS) and MO%. 
CO 4.3 vs 4.9L (p = ,005). By Cox analysis, ACE1 predicted survival 
without transplant (p=.OlS) independently of Na (.018) and low 
PCW on therapy (.081). ACE1 benefit was most apparent in pts 
with Na 2135. This study cannot determine if good hemodynamic 
response to ACE1 is itself a major predictor of survival. 
Despite titration to the same hemodynamic goals, ACE1 
reduced death in advanced heart failure compared to H/I in this 
randomized trial. 
2:30 
RANDOMIZED, MULTICENTER, DOUBLE 
CONTROLLED EVALUATION OF AMLODI 
WITH MILD-TO-MODERATE HEART FAILURE. 
Paocal Nicod, Bijoy R Ehandheria, De 
nnan, Mervin A Konstam, Robert J. 
R Moyer, D&d J. Finsky, Meyer H. Abittan, Joseph F. So&reds. 
Mount Sinai School of Medicine, New York, NY 
Previous studies have shown that calcium channel blockers (CCBs) 
are ineffective and may be deleterious in heart failure CCHF), but theee 
unfavorabk responses might not be seen with all CCBe. We conducted a 
multicenter, double-blind, placebo-controlled trial of a new CC 
amlodipine (AML), in 118 CHF pta. All pts had class II-III symptoms, 
LV ejection fraction (EF) c 40% and were treated with digoxin and 
diuretics; 80 pts were also taking convertin 
a single-blind run-in period, pte received 
daily, n=58) or placebo WA, ~60) for 2 
variables were similar in the two groups. S 
(ExT) were aesessed before randomization 
treatment; * = P c 0.05 (8 wks vs baseline); t 
4 weeks 6 weeks 
Amlodipine ? 39 f 13 set ? 62 f 17 sec*t 
After 8 weeks of therapy, ExT 7 more with AML than PLA (I? = 0.037). In 
addition, more pta treated with AML experienced improvement in CHF 
Eleven pta on AML and 12 on PLA withdrs r J due to adverse reactions. 
In conclusion, unlike other CCBs, AML improves the exercise 
capacity of pts with mild-to-moderate CHF. The mechanism by which 
AML exerts this effect is unknown, but it may ir olve action of the 
drug to reduce sympathetic activity in CHF. 
2:s 
LONG TERM CLINICAL AND NEUROHORMONAL EFFECTS OF NICARDI- 
PINE IN PATIENTS WITH SEVERE HEART FAILURE ON MAINTENANCE 
THERAPY WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS 
2:4S 
DOUBLE-BLIND, PLACEBO-CONTROLLED (P), COHPARISON OF 
ENOXIHONE (E) Ah0 DDBUTAHINE (D) INFUSIONS IN RODERATB TO 
SEWEEE CONGESTIVE HEART PAILWEE-PATIENTS (NTfiA III-IV) 
Mihai Cheorghiade, Veronica Hall, A. David Goldberg, T. 
Barry Levine, Sidney Goldstein, Heart and Vascular 
Institute, Henry Ford Hospital, Detroit, Michigan 
It ha8 been proposed that the worsening of heart failure 
(HF) with dihydropyridinee 8UCh as nicardipine is related 
EO the activation of the neuroendocrine system. To test 
this, we evaluated 20 pte with severe HF (age 55+14 yrs; 
Functional Class: NYRA III; left ventricular ejection 
fractioa[EF]:l8~8%) on maintenance therapy with captopril 
75 u&day, randomized to nicardipine 60 or 90 &day or 
placebo during a 4 mo. double-blind protocol. The follow- 
ing measurements were obtained at baseline (B) monthly x 
4 or last follow-up (F): rest and exercise radionuclide 
ventriculography (RVG EF), maximal treadmill time (T) ,and 
6-minute walking test distance (W), serum norepinephrine 
(Nor) and aldosterone (Aldo) concentrations and plasma 
renin activity. During follow-up, worsening of HF oc- 
cursed in 6 pts in the nicardipine group and 2 pts on 
placebo (p=O. 06). 
Nor Renin Aldo 
(PBhl) (ng/ml/hr) 
B F B F 
(pgg/W 
F 
Placebo 6782499 6912524 162~7 11+13 10+7 15+1 
Nicardipine 5322247 5642303 7+ 6 22728* Flz9 lli7 
*p CO.05 comparea to B 
In the 6 Nicardipine pts who deteriorated, renin increased 
from 424 to 21+15 ng/ml/hr (p=O.OOl). The T time, W  dis- 
tance, and exercise RVG EF at the last follow-up did not 
change in pta who did not deteriorate with HF in the P or 
N groupI compared to baseline. In this group of pts with 
severe EF receiving captopril, nicardipine caused worsen- 
ing of HF without an increase in serum Nor and Aldo. 
Edward Gilbert, N.D., For The Enoximone Working Group, 
University of Utah, School of Medicine, Salt Lake City, UT 
Enoximone is a selective PDg Type III inhibitor that has 
both inotropic and vasodilatory properties. This study 
compared the hemodynamic response of B to P for 24 hours 
and to open-labeled D for 48 hours. 136 p 
enrolled. At baseline treatment groups were comparable. 
Heen CI CC/ain/m2) ~88 1.79 g, 1.79 D, and 1.88 PO PCWP 
(mmIig) was 25.6 E, 25.8 0, and 26.0 P. After 48 hours pa- 
tients were transferred to standard oral therapy. Serial 
24-hour Halter recording8 were obtained to assess proer- 
rhythmic potential. Statistically significant improvement 
was found in multiple hemodynamic parameters for both E 
and D compared to P. Compared to D, E was more effective 
in reducing PCWP and more patients tolerated switching to 
oral therapy (E 65% vs D 49%). Adverse events were report- 
ed with equal frequency for D and E patients. Both active 
compound8 increased ventricular ectopy compared to P. 
PCWP mmIig -6.Omeb il.0 -2.4 k1.3 -1.6 kO.9 
SVR d.sBc.cm2 -647a f 73 -489“ i 70 -78 58 e 
PVR d.sec.cm8 -99a + 23 -106s + 26 
Hean PVWHR 126. i 32 77a 25 f Ll ; 26 
DrOpOUt 4 (8.7%) 9 (20.9%) 5 (10.6%) 
Eeaths 1 (fw 1 (HI) 0 _ 
a: P<.OS, E or D compared to P; b: P<.O5, E compared to D 
CONCi&SION: Enoximone is effective Tn improving the hemo- 
dynamic status in patients with moderate to severe CHF and 
is tolerated at least as well as dobutamine. Continuous 
infusion was associated with increased ventricular ectopy 
with both active compounds. 
